CG020 Genomika
Přednáška 12
Praktické aplikace genomiky
Jan Hejátko
Funkční genomika a proteomika rostlin,
Středoevropský technologický institut (CEITEC)
a
Národní centrum pro výzkum biomolekul,
Přírodovědecká fakulta,
Masarykova univerzita, Brno
hejatko@sci.muni.cz, www.ceitec.eu
2
 Literární zdroje ke kapitole 12:
Broughton, J.P., Deng, X., Yu, G., Fasching, C.L., Servellita, V., Singh, J., Miao, X., Streithorst,
J.A., Granados, A., Sotomayor‐Gonzalez, A., Zorn, K., Gopez, A., Hsu, E., Gu, W., Miller,
S., Pan, C.Y., Guevara, H., Wadford, D.A., Chen, J.S., and Chiu, C.Y. (2020). CRISPR‐Cas12‐
based detection of SARS‐CoV‐2. Nat Biotechnol 38, 870‐874.
Dietel, M., and Sers, C. (2006). Personalized medicine and development of targeted therapies:
The upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch 448,
744‐755.
Gaudelli, N.M., Komor, A.C., Rees, H.A., Packer, M.S., Badran, A.H., Bryson, D.I., and Liu, D.R.
(2017). Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage.
Nature 551, 464‐471.
Goh, K.I., Cusick, M.E., Valle, D., Childs, B., Vidal, M., and Barabasi, A.L. (2007). The human
disease network. Proc Natl Acad Sci U S A 104, 8685‐8690.
Chen, J.S., Ma, E., Harrington, L.B., Da Costa, M., Tian, X., Palefsky, J.M., and Doudna, J.A.
(2018). CRISPR‐Cas12a target binding unleashes indiscriminate single‐stranded DNase
activity. Science 360, 436‐439.
Koblan, L.W., Erdos, M.R., Wilson, C., Cabral, W.A., Levy, J.M., Xiong, Z.M., Tavarez, U.L.,
Davison, L.M., Gete, Y.G., Mao, X., Newby, G.A., Doherty, S.P., Narisu, N., Sheng, Q.,
Krilow, C., Lin, C.Y., Gordon, L.B., Cao, K., Collins, F.S., Brown, J.D., and Liu, D.R. (2021). In
vivo base editing rescues Hutchinson‐Gilford progeria syndrome in mice. Nature.
Li, X., Qian, X., Wang, B., Xia, Y., Zheng, Y., Du, L., Xu, D., Xing, D., DePinho, R.A., and Lu, Z.
(2020). Programmable base editing of mutated TERT promoter inhibits brain tumour
growth. Nat Cell Biol 22, 282‐288.
Literatura
3
 Lékařství
 Molekulární diagnostika
 Individualizovaná medicína
 Genová terapie
 Biotechnologie
 Geneticky Modifikované Organismy
 Transgenoze
 Editování genomu
 Modelové organismsy
 Principy PCR
Osnova
4
 Lékařství
 Molekulární diagnostika
Osnova
5
Molekulární Diagnostika
 Cca 10,000 onemocnění u člověka je podmíněno mutací v
jediném genu
 cystická fibróza
 srpkovitá anémie
 svalová dystrofie
 β-talasémie
 ….
 Časná molekulární diagnostika
 mutace nebo infekce
 PCR
 Hybridizace na DNA čipu hybridization
 Cas-based
6
Molekulární Diagnostika
 Mammoth Biosciences
 Spoluzakladatelka Jenifer Doudna https://youtu.be/IPe4IdgKGdQ
7
 Lékařství
 Molekulární diagnostika
 Individualizovaná medicína
Osnova
8
Individualizovaná
Medicína
 Využívá znalost genomu pro:
 Předpověď zdravotních rizik
 Diagnositku
 Výběr nejvhodnějšího typu léčby
 minimalizuje nežádoucí efekty léčby
 prevence
http://www.personalizedmedicinecoalition.org/
9 http://www.personalizedmedicinecoalition.org/
Individualizovaná
Medicína
10
Individualizovaná
Medicína
11
http://www.personalizedmedicinecoalition.org/
Individualizovaná
Medicína
12http://www.personalizedmedicinecoalition.org/
13http://www.personalizedmedicinecoalition.org/
14
 Problém:
 Mnohofaktoriální podmíněnost většiny lidských
onemocnění
Individualizovaná
Medicína
15
Goh et al., 2007
Genové interakce u
lidských onemocnění
16
 Řešení problému:
 Systémová biologie – využívá např. genové klastrování k identifikaci
genů asociovaných s pozorovaným jevem (nemocí, poruchou, ..)
Topotecan
-resistant
Topotecan
-sensitive
Dietel and Sers, 2006
Individualizovaná
Medicína
17
 Řešení problému:
 biomarkery
 testy
The Case for Personalized Medicine, 3rd edition
Individualizovaná
Medicína
18
 Další problémy
 Etické otázky
 Možnost zneužití znalosti genomu
 riziko: nedostatečná ochrana dat
 V některých zemích je uzákoněn omezený přístup pro určité typy
zaměstnanců nebo pojišťovací společnosti
 Vysoké náklady
 Dělení medicíny na first-class and low-class služby
 Zvětšování problému globalizačního handikapu – chudé země si
nemohou takto pokročilý typ léčby dovolit
 Soukromí
 Zásadní a komplikovaná otázka
 Jakou informaci lze považovat za soukromou?
Individualizovaná
Medicína
19
 Lékařství
 Molekulární diagnostika
 Individualizovaná medicína
 Genová terapie
 Biotechnologie
Osnova
20
Procedure in which the DNA sequence is inserted into
the patient genome to replace or supplement the original
gene
 Options:
 replace the mutated gene
 repair the mutation
 deliver DNA encoding a therapeutic protein
 antisense therapy
 In the future useful for treating e.g. hereditary diseases
 Types:
 somatic gene therapy
 gene therapy of germ cells
Gene Therapy
21
Gene Therapy
 Hutchinson–Gilford progeria
syndrome
 C•G-to-T•A mutace (c.1824 C>T;
p.G608G) v genu pro laminin (LMNA)
 Defekt v sestřihu RNA vede k tvorbě
toxického proteoinu progerinu
 Věk dožití cca 14 let
 In vivo oprava pomocí ABEs potvrzena
u myší a lidských fibroblastů (Koblan et
al., 2021)
22
Adenine Base Editors
Gaudeli et al., 2017
23
Adenine Base Editors
Kuraoka, 2005
24
 Methods
 viral vectors
 retroviruses
 adenoviruses
 herpes simplex virus
 non-viral methods
 injection of plasmid DNA into muscle
 increased efficiency of DNA delivery
 electroporation
 sonoporation
 „gene gun“ (biolistic)
 magnetofection
 genome editing
Gene Therapy
25
Ethical Issues
 Regulace editace genomu v zemědělství a lidském zdraví
 https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/
 International Commission on the Clinical Use of Human
Germline Genome Editing
 convened by the U.S. National Academy of Medicine (NAM), the U.S.
National Academy of Sciences (NAS), and the Royal Society of the U.K. …
 …to identify a number of scientific, medical, and ethical requirements that
should be considered, and could inform the development of a potential
pathway from research to clinical use — if society concludes that heritable
human genome editing applications are acceptable
 more details at https://nationalacademies.org/gene-editing/international-
commission/index.htm
26
Ethical Issues
 Alliance for Regenerative Medicine
 international group representing the cell and gene therapy sector
 put out a “statement of principles” on genome editing endorsed by 13 of the
most active companies in this field
 changing heritable DNA in sperm, eggs or a new embryo — came true in
November 2018 when He Jiankui, a Chinese biophysicist, said that his lab had
edited two baby girls to make them resistant to HIV infection. This mutation will
be inherited by their descendants.
 31 clinical trials for gene edited therapies are in progress around the world, 20
of which are in oncology. None is yet close to commercialization. The US has
the largest number of trials (19) followed by China (10) and the UK (6)
FT, Clive Cookson, Science Editor August 27 2019
27
Ethical Issues
 Genome editing as a bioweapon?
 ongoing research program funded by the U.S. Defense Advanced Research
Projects Agency (DARPA)
 aims to disperse infectious genetically modified viruses that have been
engineered to edit crop chromosomes directly in fields
 the means of delivery of these viral horizontal environmental genetic alteration
agents (HEGAAs) into the environment should be insect-based dispersion
 Part of scientific community does not find the program useful for the U.S.
agriculture, but points to its possible misuse
28
Editing as a bioweapon?
Reeves et al., 2018
29
 Medicine
 Molecular Diagnosis
 Personalized Medicine
 Gene Therapy
 Biotechnology
Outline
30
BIOTECHNOLOGY
 It uses living organisms, cells or parts of cells (enzymes) for
research, leading to new products and applications in
medicine, agriculture, food, environmental protection
 Also used in developing better/sustainable production
methods for the chemical industry and other industrial
processes
 An interdisciplinary approach requiring knowledge of
chemistry, biology, physics, material sciences, engineering
and informatics
 The origin of biotechnology can be traced 4,000 years back,
when the Sumerians (although not knowingly) used microbes
for the production of alcoholic beverages.
31
BIOTECHNOLOGY
 Examples
 effective utilization of plant biomass for fuel production
 acquisition of starting material (monomers) for the
production of polymers from living organisms instead of
from fossil sources
 phytopharmaceuticals – using plants in new vaccination
methods such as expression of antibodies or antigens
suitable for immunization
 European Federation of Biotechnology
http://www.efb-central.org
32
 Lékařství
 Molekulární diagnostika
 Individualizovaná medicína
 Genová terapie
 Biotechnologie
 Geneticky Modifikované Organismy
 Transgenoze
Osnova
33
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
1961 1997 2050
hectarespercapita
Source: UN Millennium Ecosystem Assessment
Human Population vs
Arable Land Availability
34
Nutrition Deficiency
https://qz.com/africa/1064653/the-world-could-run-out-of-food-two-decades-earlier-than-thought/
…as soon as in 2027?
The world-total deficiency in food production of…
35
 organisms naturally vary due to mutations
 before the era of genetic engineering question
of chance
 breeding tools
 selection and crossing
 modern breeder learned to change hereditary
information – increase the mutants allele
frequency
 chemicals, radiation ...
 results are incidental/non-targeted
Success
is not always visible at a glance
Breeding
36
 Targeted modification ("targeted breeding")
 ability to transfer genes = transgenosis
 the first practical application: production of
human insulin in bacteria - 1978
Genetic Engineering
37
Plant Transgenosis
https://www.youtube.com/watch?v=yesNHd9h8k0
38
Breeding Vs. Genetic Engineering
39
 Organisms carrying modified genetic information –
either own or foreign (from another organism),
enabling targeted changes in the organism and its
use for specific purposes
 GMOs
 plants
 bacteria
 animals
http://www.gmo-compass.org/
Geneticaly Modified Organisms
(GMOs)
40
 resistance to pests
 herbicide resistance
 resistance to drought
 resistance to cold
 resistance to salinity
 more efficient nitrogen utilization
 increasing nutritional quality
http://ipbo.vib-ugent.be/
Geneticaly Modified Plants
41
 resistance to insect pests
 corn, cotton, rice
 genes from Bacillus thuringiensis
(Bt)
 Expression of crystalline deltaendotoxins
- Crystal (Cry) proteins
 increasing yields, reducing the
amount of chemical sprays
Bt Plants
42
Bt Plants
43
Ht Plants
 resistance to systemic herbicides
 glyphosate
 interferes with the synthesis of aromatic amino acids; animals
without the appropriate enzymatic apparatus = harmless
 blocks the enzyme 5-enolpyrovylshikimate-3-phosphate
synthase (EPSPS) in chloroplasts – affects green plants
 ineffective for bacterial EPSPS - evolutionarily divergent
 soya, maize, sugar beet, canola, cotton, alfalfa - added
enzyme for tolerance
 company Bayer (Monsanto), trade name Roundup
44
Ht Plants
 resistance to systemic herbicides
 glufosinate (phosphinothricin)
 prevents processing of ammonium - toxic
 Streptomyces hygroscopicus synthesizes and transforms it:
acetylation by the enzyme phosphinothricin acetyltransferase
– coding gene isolated in 1987 - named bar
 trade names: Basta, Liberty, Finale, Radical ...
45
Multiresistant Plants
 Bt resistance + herbicide
 multiresistant corn - the majority of total
production in the USA
 example of multiresistant corn:
 three Bt genes for resistance to air pests
 three Bt genes for resistance against soil pests
 two genes for herbicide resistance
46
 viruses - no chemical agents available
 gene encoding non-infectious viral envelope protein increases
resistance to viral infection
 banana; papaya - Hawaii, Southeast Asia
 cassava - a basic food ingredient for more than 500 million people +
animal feed
Disease-Tollerant Plants
47
 Chickpeas - more resistant to
drought, but toxic
 GMOs with inactivated toxin
 Corn resistant to drought
Lathyrus sativus
Chickpea
Cereals
Drought in Ethiopia
Disease- and Stress-Tollerant Plants
48
 use of nitrogen from fertilizers
 rice with gene from barley - 3x higher nitrogen utilization
under oxygen deficiency
Nitrogen Use Efficiency
49
 Golden rice
 several genes from maize encoding enzymes
for the biosynthesis of β-carotene (precursor of
vitamin A)
 Canola and Soybean
 improved oil properties: stable, resistant to high
temperatures, long storage
Improved Nutrition Value
50
 Transgenic cats
 lentiviruses are sensitive to restriction factors
 specific restriction factor: rhesus macaque TRIMCyp + eGFP
 uniform expression, no mosaicity and no silencing in F1 generation
 lymphocytes of transgenic animals resistant to replication of FIV
Wongsrikeao et al., 2011, Nature Methods
GMO Animals
51
 Lékařství
 Molekulární diagnostika
 Individualizovaná medicína
 Genová terapie
 Biotechnologie
 Geneticky Modifikované Organismy
 Transgenoze
 Editování genomu
Osnova
52
Gene Editing in Plant
Domestication
53
 Lékařství
 Molekulární diagnostika
 Individualizovaná medicína
 Genová terapie
 Biotechnologie
 Geneticky Modifikované Organismy
 Transgenoze
 Editování genomu
 Modelové organismy
Osnova
54
 Low requirements for area
 Relatively large number of offspring (3-14, 6-8 on
average)
 Genome size is close to the size of human genome
(about 3000 Mbp), the number of genes as well (about
24K)
 20 chromosomes (19+1)
 Suitable for a wide range of physiological experiments
(anatomical and physiological similarity to human)
 Possibility to obtain (quite easily) KO mutants and
transgenic lines
Mus musculus
house mouse
55
 Genome known since 2002
(http://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/mouse/)
Mus musculus
house mouse
56
 Low requirements for cultivation area
Arabidopsis thaliana
mouse-ear cress
 High number of seeds (20.000 per plant and more)
 Small and compact genome, (125 MBp, about
25.000 genes, average size 3 kb)
 5 chromosomes
 Suitable for wide range od physiological experiments
 High natural variability (approximately 750 ecotypes
(Nottingham Arabidopsis Seed Stock Centre))
Columbia 0 Landsberg 0 Wassilewskija 0
http://seeds.nottingham.ac.uk/
57
Arabidopsis thaliana
mouse-ear cress
 Genome known since 2000 (http://www.arabidopsis.org/)
58
 Lékařství
 Molekulární diagnostika
 Individualizovaná medicína
 Genová terapie
 Biotechnologie
 Geneticky Modifikované Organismy
 Transgenoze
 Editování genomu
 Modelové organismsy
 Principy PCR
Osnova
59
60
 Techniky využivající pokročilé přístupy zásadním,
způsobem mění naše možnost v medicíně i
zemědělství
 Možnost programovatelné editace genomu slibuje
zásadní obrat v léčbě zejména dědičně
podmíněných chorob a ve šlechtění nových odrůd i
ras
 Je nezbytná přísná kontrola s jasně nastavenými
pravidly pro všechny, ale nikoliv úplný zákaz
Klíčové koncepty
61
Diskuse